(Press-News.org) (ORLANDO, Dec. 9, 2025) – In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data were presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
“We were able to prove that pirtobrutinib is an excellent drug both in terms of efficacy and tolerance,” said lead study author Wojciech Jurczak, MD, PhD, professor of hematology at the National Research Institute of Oncology in Kraków, Poland. “Our data show that it is not just overcoming resistance but is even more specific and selective than previous BTK inhibitors.”
Previous studies have shown pirtobrutinib, a first-generation non-covalent BTK inhibitor, to be efficacious against CLL/SLL that is relapsed or refractory after initial treatments. The current trial is the first to use pirtobrutinib in a first-line setting against a combination of bendamustine, a chemotherapy, and rituximab, a monoclonal antibody, which together constitute a common first-line combination treatment for CLL/SLL.
BTK inhibitors work by blocking the BTK enzyme, which plays a role in B cell growth and proliferation. Pirtobrutinib is developed to overcome the tendency for cancer cells to become resistant to previous-generation covalent BTK inhibitors.
CLL and SLL are slow-growing forms of non-Hodgkin lymphoma that develop when lymphocytes grow out of control and abnormal B cells build up in bone marrow (CLL) or lymph nodes (SLL). Each year, an estimated 4.5 out of every 100,000 adults are diagnosed with CLL or SLL.
The trial randomized 282 patients to receive a daily oral dose of pirtobrutinib continuously unless they developed unacceptable side effects, or six cycles of BR, administered via intravenous infusion every 28 days. At a median follow-up of 28 months, the rate of progression-free survival was significantly better with pirtobrutinib (93.4%) versus BR (70.7%), meeting the trial’s primary endpoint.
The progression-free survival trends were consistent across subgroups including among patients of different ages and among patients with or without Immunoglobin Heavy Chain Variable (IGHV) mutations, supporting pirtobrutinib as a new standard of care for first-line CLL/SLL treatment, said Dr. Jurczak. He noted that pirtobrutinib is more convenient for patients compared with covalent BTK inhibitors, some of which involve complex requirements around the timing of administration in relation to eating and drinking.
Overall survival will be formally assessed at a later date given the need for longer follow-up, but preliminary results favor pirtobrutinib for this secondary endpoint. Over half (52.9%) of patients in the BR arm who experienced disease progression crossed over to receive pirtobrutinib. From a statistical perspective, this amount of crossover would be expected to dilute any overall survival difference between study groups, so researchers noted that the trend toward improved overall survival is especially noteworthy.
Patients receiving pirtobrutinib experienced lower rates of adverse events, with 40.0% of patients in the pirtobrutinib arm experiencing treatment-related adverse events of grade 3 or higher compared with 67.4% in the BR arm. Treatment discontinuation due to adverse events was also less common in the pirtobrutinib arm (4.3%) compared with the BR arm (15.2%). The rate of atrial fibrillation or flutter in the pirtobrutinib arm was 1.4%, consistent with what would be expected among patients of a similar age in the general population.
Researchers said that the results suggest pirtobrutinib has strong potential as a first-line treatment for CLL/SLL. However, the study used a continuous administration strategy and was also limited by pirtobrutinib’s interactions with antibiotics and antifungals. To pave the way for practical adoption of pirtobrutinib as first-line treatment, Dr. Jurczak suggested that additional work is needed to develop a fixed-duration regimen for the drug and to determine which agents are best to use after pirtobrutinib if the cancer returns. He also noted that pirtobrutinib should be paused if patients develop infections during treatment, given the drug’s interaction with antibiotics and antifungals.
Additional studies are underway to assess a lower dosing strategy for pirtobrutinib and move toward fixed-duration rather than continuous administration.
This study was funded by Lilly, maker of pirtobrutinib.
Wojciech Jurczak, MD, PhD, of the National Research Institute of Oncology, will present this study on Tuesday, December 9, 2025, at 8:00 a.m. Eastern time during the Late-Breaking Abstracts Session in West Hall D2 of the Orange County Convention Center.
###
The American Society of Hematology (ASH) (hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. Since 1958, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. Join the #Fight4Hematology by visiting hematology.org/fight4hematology.
The Blood journals (https://ashpublications.org/journals) are the premier source for basic, translational, and clinical hematologic research. The Blood journals publish more peer-reviewed hematology research than any other academic journals worldwide.
END
Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL
2025-12-09
ELSE PRESS RELEASES FROM THIS DATE:
Online tracking and privacy on hospital websites
2025-12-09
Researchers find that tracking pixels—small pieces of embedded code that can transmit user data to third parties—significantly increase data breach risk on hospital websites. Hilal Atasoy and colleagues analyzed 12 years of archived website data from 1,201 large US hospitals between 2012 and 2023, examining the adoption of pixel tracking and their relationship to data breaches. The authors found pixel tracking in 66% of hospital-year observations, despite stringent privacy regulations. Hospitals using third-party pixels experienced at least a 1.4 percentage point increase in breach probability, representing a 46% ...
A freely available tool to document wartime destruction
2025-12-09
Researchers develop a method to detect the destruction of buildings using freely available satellite radar imagery. Daniel Racek and colleagues’ algorithm analyzes publicly available Sentinel-1 synthetic aperture radar images from the European Space Agency to identify destroyed buildings in conflict zones. The method statistically assesses the visual similarity of locations over time, enabling detection of destruction from a single satellite image every 12 days, without requiring labeled training data or expensive proprietary imagery. Unlike optical ...
Residential solar panels can raise electricity rates
2025-12-09
A modeling study shows how under some conditions, increasing numbers of households with rooftop solar panels can lead to higher rates for those without their own solar system. When utility customers cancel their accounts after switching to residential solar panels, the utility must spread their fixed costs around to a smaller number of remaining customers, which can lead to rate increases. Charles Sims and colleagues studied how this pecuniary externality affects different income groups using agent-based computational economic modeling of the Tennessee Valley Authority (TVA), an area with some of the highest poverty rates in the United States. The authors asked 2,307 TVA residential customers ...
Scientists use synthetic platelets as ‘Trojan horse’ drug-delivery system
2025-12-09
CLEVELAND—Scientists working to enhance brain-computer interface (BCI) technology—which allows people to control devices with their thoughts—have found they can improve the performance of electrodes implanted in the brain by targeted delivery of anti-inflammatory drugs.
Case Western Reserve University researchers, in collaboration with Haima Therapeutics, used a novel “platelet-inspired nanoparticle” to deliver an anti-inflammatory drug directly to where BCI electrodes were implanted. The drug doubled the effectiveness of ...
Cooperative Intermolecular Interactions Regulate Supramolecular Polymer Assembly
2025-12-09
Supramolecular chemistry involves the study of self-assembly of discrete molecules that are used to build functional large structures. Often, these molecules are allowed to self-assemble into one-dimensional polymeric structures (supramolecular polymers or SPs) in a suitable environment, and the dynamic molecular interactions are noted for tweaking the environment and improving the features of the resulting SPs. They are being explored as the next-generation polymeric materials with applications in electronics, soft-robotics, ...
Korea University researchers develop ultrasensitive method to detect low-frequency cancer mutations
2025-12-09
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.
To address this challenge, researchers led by Professor Junseok W Hur from Korea University College of Medicine, in collaboration with multiple partners, have developed MUTE-Seq, a highly sensitive CRISPR-based method designed to detect cancer mutations present at exceptionally low frequencies while simultaneously reducing sequencing costs and background error noise. The study was first made available ...
First patient enrolled in GOG-3133/ FRAmework-01 phase 3 study evaluating sofetabart mipitecan (LY4170156), a novel ADC targeting folate receptor alpha (FRα), in recurrent ovarian cancer
2025-12-09
Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart Mipitecan (LY4170156), a Novel ADC Targeting Folate Receptor Alpha (FRα), in Recurrent Ovarian Cancer
The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3133, a pivotal Phase 3 clinical trial titled FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. The study is sponsored by Eli ...
Two Hebrew University researchers win prestigious ERC consolidator grants
2025-12-09
The Hebrew University of Jerusalem proudly congratulates two of its esteemed researchers on receiving the prestigious European Research Council (ERC) Consolidator Grant for 2025. Both awardees, who lead groundbreaking work in applied physics and international relations, were selected for one of Europe’s most competitive grants, awarded to researchers 7–12 years after their doctorates. These grants support the establishment of independent research groups, the development of new laboratories, and innovative projects across the natural sciences, social sciences, and humanities. This recognition continues the university’s ...
ERC grant helps to quantify the impact of anthropogenic air pollution particles on climate
2025-12-09
University of Tartu Associate Professor in Climate Physics Velle Toll received the Consolidator Grant from the European Research Council (ERC) to quantify the extent to which air pollution particles cool the Earth’s climate. The results of Toll’s work would help fill a gap in our detailed understanding of human-induced climate change and improve the accuracy of climate projections.
The main cause of anthropogenic climate change is the greenhouse gases released by burning fossil fuels, and the ...
Exercise might help improve mobility during aging
2025-12-09
The brain-chemical surge that comes with running may bolster coordination and speed in the old and young alike, a new study of middle-aged mice shows. Such physical activity may help restore ease of movement and agility, which often decline as humans and animals get older, the study authors said.
Led by NYU Langone Health researchers, the investigation explored how aerobic exercise can boost the release of dopamine, a brain chemical involved in movement, reward, and memory. The team built upon its earlier work, which revealed that young (10-week-old) male rodents had a lasting increase in dopamine release after voluntarily running on an exercise wheel for 30 days. The new findings showed ...